Aug 31, 2016
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF) The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understand...
Read More...
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Jan 30, 2026
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
Newsletter/Whitepaper